-
2
-
-
33847276516
-
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-arm cooperative study in Japan
-
Y. Ohe, Y. Ohashi, and K. Kubota et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan Ann Oncol 18 2007 317
-
(2007)
Ann Oncol
, vol.18
, pp. 317
-
-
Ohe, Y.1
Ohashi, Y.2
Kubota, K.3
-
3
-
-
0037050352
-
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
-
J.H. Schiller, D. Harrington, and C.P. Belani et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92
-
(2002)
N Engl J Med
, vol.346
, pp. 92
-
-
Schiller, J.H.1
Harrington, D.2
Belani, C.P.3
-
5
-
-
77955362168
-
Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: An international validation study
-
C.M. Bryant, D.L. Albertus, and S. Kim et al. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study PLoS One 5 2010 e11712
-
(2010)
PLoS One
, vol.5
, pp. 11712
-
-
Bryant, C.M.1
Albertus, D.L.2
Kim, S.3
-
6
-
-
54549094903
-
Somatic mutations affect key pathways in lung adenocarcinoma
-
L. Ding, G. Getz, and D.A. Wheeler et al. Somatic mutations affect key pathways in lung adenocarcinoma Nature 455 2008 1069
-
(2008)
Nature
, vol.455
, pp. 1069
-
-
Ding, L.1
Getz, G.2
Wheeler, D.A.3
-
7
-
-
75749097259
-
Targeted therapies for non-small cell lung cancer
-
W.C. Dempke, T. Suto, and M. Reck Targeted therapies for non-small cell lung cancer Lung Cancer 67 2010 257
-
(2010)
Lung Cancer
, vol.67
, pp. 257
-
-
Dempke, W.C.1
Suto, T.2
Reck, M.3
-
8
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
-
E.L. Kwak, Y.J. Bang, and D.R. Camidge et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693
-
(2010)
N Engl J Med
, vol.363
, pp. 1693
-
-
Kwak, E.L.1
Bang, Y.J.2
Camidge, D.R.3
-
10
-
-
79955720082
-
Anticancer therapy with checkpoint inhibitors: What, where and when?
-
M.D. Garrett, and I. Collins Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci 32 2011 308
-
(2011)
Trends Pharmacol Sci
, vol.32
, pp. 308
-
-
Garrett, M.D.1
Collins, I.2
-
11
-
-
0034707047
-
The DNA damage response: Putting checkpoints in perspective
-
B.B. Zhou, and S.J. Elledge The DNA damage response: putting checkpoints in perspective Nature 408 2000 433
-
(2000)
Nature
, vol.408
, pp. 433
-
-
Zhou, B.B.1
Elledge, S.J.2
-
12
-
-
0035093737
-
DNA double-strand breaks: Signaling, repair and the cancer connection
-
K.K. Khanna, and S.P. Jackson DNA double-strand breaks: signaling, repair and the cancer connection Nat Genet 27 2001 247
-
(2001)
Nat Genet
, vol.27
, pp. 247
-
-
Khanna, K.K.1
Jackson, S.P.2
-
13
-
-
13944266820
-
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
-
C.S. Sorensen, L.T. Hansen, and J. Dziegielewski et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair Nat Cell Biol 7 2005 195
-
(2005)
Nat Cell Biol
, vol.7
, pp. 195
-
-
Sorensen, C.S.1
Hansen, L.T.2
Dziegielewski, J.3
-
14
-
-
58149500122
-
Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells
-
L.A. Parsels, M.A. Morgan, and D.M. Tanska et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells Mol Cancer Ther 8 2009 45
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 45
-
-
Parsels, L.A.1
Morgan, M.A.2
Tanska, D.M.3
-
15
-
-
77950650401
-
In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762
-
J.B. Mitchell, R. Choudhuri, and K. Fabre et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762 Clin Cancer Res 16 2010 2076
-
(2010)
Clin Cancer Res
, vol.16
, pp. 2076
-
-
Mitchell, J.B.1
Choudhuri, R.2
Fabre, K.3
-
16
-
-
77953770987
-
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair
-
M.A. Morgan, L.A. Parsels, and L. Zhao et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair Cancer Res 70 2010 4972
-
(2010)
Cancer Res
, vol.70
, pp. 4972
-
-
Morgan, M.A.1
Parsels, L.A.2
Zhao, L.3
-
17
-
-
39749185974
-
Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest
-
A.A. Levesque, A.A. Fanous, A. Poh, and A. Eastman Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest Mol Cancer Ther 7 2008 252
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 252
-
-
Levesque, A.A.1
Fanous, A.A.2
Poh, A.3
Eastman, A.4
-
18
-
-
0035399861
-
Cytokine-responsive gene-2/IFN-inducible protein-10 expression in multiple models of liver and bile duct injury suggests a role in tissue regeneration
-
L.G. Koniaris, T. Zimmers-Koniaris, E.C. Hsiao, K. Chavin, J.V. Sitzmann, and J.M. Farber Cytokine-responsive gene-2/IFN-inducible protein-10 expression in multiple models of liver and bile duct injury suggests a role in tissue regeneration J Immunol 167 2001 399
-
(2001)
J Immunol
, vol.167
, pp. 399
-
-
Koniaris, L.G.1
Zimmers-Koniaris, T.2
Hsiao, E.C.3
Chavin, K.4
Sitzmann, J.V.5
Farber, J.M.6
-
19
-
-
33751581196
-
Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics
-
Z. Chen, Z. Xiao, and W.Z. Gu et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics Int J Cancer 119 2006 2784
-
(2006)
Int J Cancer
, vol.119
, pp. 2784
-
-
Chen, Z.1
Xiao, Z.2
Gu, W.Z.3
-
20
-
-
49149129916
-
Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study
-
K. Shedden, J.M. Taylor, and S.A. Enkemann et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study Nat Med 14 2008 822
-
(2008)
Nat Med
, vol.14
, pp. 822
-
-
Shedden, K.1
Taylor, J.M.2
Enkemann, S.A.3
-
21
-
-
52949139387
-
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
-
S.D. Zabludoff, C. Deng, and M.R. Grondine et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies Mol Cancer Ther 7 2008 2955
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 2955
-
-
Zabludoff, S.D.1
Deng, C.2
Grondine, M.R.3
-
22
-
-
0035710746
-
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method
-
K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method Methods 25 2001 402
-
(2001)
Methods
, vol.25
, pp. 402
-
-
Livak, K.J.1
Schmittgen, T.D.2
-
23
-
-
84863288259
-
Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma
-
L. Lin, A.J. Bass, and W.W. Lockwood et al. Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma Proc Natl Acad Sci U S A 109 2012 4251
-
(2012)
Proc Natl Acad Sci U S A
, vol.109
, pp. 4251
-
-
Lin, L.1
Bass, A.J.2
Lockwood, W.W.3
-
24
-
-
0035480005
-
Tissue microarrays (TMAs) for high-throughput molecular pathology research
-
A. Nocito, J. Kononen, O.P. Kallioniemi, and G. Sauter Tissue microarrays (TMAs) for high-throughput molecular pathology research Int J Cancer 94 2001 1
-
(2001)
Int J Cancer
, vol.94
, pp. 1
-
-
Nocito, A.1
Kononen, J.2
Kallioniemi, O.P.3
Sauter, G.4
-
25
-
-
0034018946
-
Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays
-
S. Wang, M.H. Saboorian, E. Frenkel, L. Hynan, S.T. Gokaslan, and R. Ashfaq Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays J Clin Pathol 53 2000 374
-
(2000)
J Clin Pathol
, vol.53
, pp. 374
-
-
Wang, S.1
Saboorian, M.H.2
Frenkel, E.3
Hynan, L.4
Gokaslan, S.T.5
Ashfaq, R.6
-
26
-
-
0021244486
-
Mean inactivation dose: A useful concept for intercomparison of human cell survival curves
-
B. Fertil, H. Dertinger, A. Courdi, and E.P. Malaise Mean inactivation dose: a useful concept for intercomparison of human cell survival curves Radiat Res 99 1984 73
-
(1984)
Radiat Res
, vol.99
, pp. 73
-
-
Fertil, B.1
Dertinger, H.2
Courdi, A.3
Malaise, E.P.4
-
27
-
-
23044492007
-
Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine
-
M.A. Morgan, L.A. Parsels, J.D. Parsels, A.K. Mesiwala, J. Mybaum, and T.S. Lawrence Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine Cancer Res 65 2005 6835
-
(2005)
Cancer Res
, vol.65
, pp. 6835
-
-
Morgan, M.A.1
Parsels, L.A.2
Parsels, J.D.3
Mesiwala, A.K.4
Mybaum, J.5
Lawrence, T.S.6
-
28
-
-
84859611140
-
Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy
-
M. Bartucci, S. Svensson, and P. Romania et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy Cell Death Diff 19 2012 768
-
(2012)
Cell Death Diff
, vol.19
, pp. 768
-
-
Bartucci, M.1
Svensson, S.2
Romania, P.3
-
29
-
-
84874411631
-
Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells
-
D. Minami, N. Takigawa, and H. Takeda et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells Mol Cancer Res 11 2013 140
-
(2013)
Mol Cancer Res
, vol.11
, pp. 140
-
-
Minami, D.1
Takigawa, N.2
Takeda, H.3
-
30
-
-
0035829685
-
Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells
-
K. Koniaras, A.R. Cuddihy, H. Christopoulos, A. Hogg, and M.J. O'Connell Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells Oncogene 20 2001 7453
-
(2001)
Oncogene
, vol.20
, pp. 7453
-
-
Koniaras, K.1
Cuddihy, A.R.2
Christopoulos, H.3
Hogg, A.4
O'Connell, M.J.5
-
31
-
-
84864658154
-
Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma
-
O.D. Roe, A. Szulkin, and E. Anderssen et al. Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma PLoS One 7 2012 e40521
-
(2012)
PLoS One
, vol.7
, pp. 40521
-
-
Roe, O.D.1
Szulkin, A.2
Anderssen, E.3
-
32
-
-
78649896033
-
Expression of checkpoint kinase 1 and polo-like kinase 1 and its clinicopathological significance in benign and malignant lesions of the stomach
-
H. Yao, Z. Yang, and Y. Li Expression of checkpoint kinase 1 and polo-like kinase 1 and its clinicopathological significance in benign and malignant lesions of the stomach Zhong Nan Da Xue Xue Bao Yi Xue Ban 35 2010 1080
-
(2010)
Zhong Nan da Xue Xue Bao Yi Xue Ban
, vol.35
, pp. 1080
-
-
Yao, H.1
Yang, Z.2
Li, Y.3
-
33
-
-
84865635727
-
Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition
-
V.A. Venkatesha, L.A. Parsels, and J.D. Parsels et al. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition Neoplasia 14 2012 519
-
(2012)
Neoplasia
, vol.14
, pp. 519
-
-
Venkatesha, V.A.1
Parsels, L.A.2
Parsels, J.D.3
-
34
-
-
84455174466
-
Treatment with the Chk1 inhibitor Go6976 enhances cisplatin cytotoxicity in SCLC cells
-
R. Thompson, M. Meuth, P. Woll, Y. Zhu, and S. Danson Treatment with the Chk1 inhibitor Go6976 enhances cisplatin cytotoxicity in SCLC cells Int J Oncol 40 2012 194
-
(2012)
Int J Oncol
, vol.40
, pp. 194
-
-
Thompson, R.1
Meuth, M.2
Woll, P.3
Zhu, Y.4
Danson, S.5
-
35
-
-
18544384850
-
Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics
-
Z. Xiao, J. Xue, D. Semizarov, T.J. Sowin, S.H. Rosenberg, and H. Zhang Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics Int J Cancer 115 2005 528
-
(2005)
Int J Cancer
, vol.115
, pp. 528
-
-
Xiao, Z.1
Xue, J.2
Semizarov, D.3
Sowin, T.J.4
Rosenberg, S.H.5
Zhang, H.6
-
36
-
-
79957916529
-
Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition
-
L.A. Parsels, Y. Qian, and D.M. Tanska et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition Clin Cancer Res 17 2011 3706
-
(2011)
Clin Cancer Res
, vol.17
, pp. 3706
-
-
Parsels, L.A.1
Qian, Y.2
Tanska, D.M.3
|